Vincristinesulfaat Teva 1 mg/ml

DRUG2 trials

Sponsors

Princess Maxima Center For Pediatric Oncology, Day One Biopharmaceuticals Inc.

Conditions

Acute lymphoblastic leukemiaPediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

Phase 3

Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia

SuspendedCTIS2022-502503-30-00

Princess Maxima Center For Pediatric OncologyAcute lymphoblastic leukemia

Start: 2022-12-15Target: 206Updated: 2026-01-27

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

RecruitingCTIS2024-510742-13-00

Day One Biopharmaceuticals Inc.Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

Start: 2023-04-19Target: 245Updated: 2025-11-19